[The effectiveness of eprosartan in patients with chronic glomerulonephritis].
The subjects of this 12-week open non-controlled study of the organoprotective efficiency of eprosartan were 15 patients with chronic glomerulonephritis. The results of the investigation demonstrated high organoprotective activity of eprosartan in a dose of 600 mg a day, which manifested by anti-proteinuric and anti-hematuric effects, as well as positive changes in the parameters of intragromerular filtration, reduction of left ventricular hypertrophy and rigidity, and normalization of the vascularmotor function of the brachial arterial endothelium. To a large extent, the organoprotective activity of eprosartan depends on the unique pharmacodynamic profile of this drug, which is able to decrease excessive functional activity of the sympathetico-adrenal system, which is reflected in the dynamics of the cardiac rhythm dispersion parameters.
Kaliuzhina
E V
EV
Zibnitskaia
L I
LI
Surkova
L G
LG
Solovtsev
M A
MA
Konaplev
D I
DI
Kolesnikov
R N
RN
Kaliuzhin
V V
VV
D000179:Acrylates / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D005260:Female; D005921:Glomerulonephritis / Q000188:drug therapy*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D013876:Thiophenes / Q000627:therapeutic use*
D000179:Acrylates; D000806:Angiotensin-Converting Enzyme Inhibitors; D007093:Imidazoles; D013876:Thiophenes; C068373:eprosartan